# Apatinib Plus Camrelizumab Combined With Docetaxel and S1 in First-line Treatment for Metastatic Gastric Cancer

> **NCT04781686** · PHASE2 · UNKNOWN · sponsor: **Zhou Fuxiang** · enrollment: 35 (estimated)

## Conditions studied

- Metastatic Gastric Adenocarcinoma
- Metastatic Gastroesophageal Junction Adenocarcinoma

## Interventions

- **DRUG:** Camrelizumab
- **DRUG:** Apatinib Mesylate
- **DRUG:** S1
- **DRUG:** Docetaxel injection

## Key facts

- **NCT ID:** NCT04781686
- **Lead sponsor:** Zhou Fuxiang
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-05-14
- **Primary completion:** 2024-08
- **Final completion:** 2025-08
- **Target enrollment:** 35 (ESTIMATED)
- **Last updated:** 2021-05-17

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04781686

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04781686, "Apatinib Plus Camrelizumab Combined With Docetaxel and S1 in First-line Treatment for Metastatic Gastric Cancer". Retrieved via AI Analytics 2026-07-13 from https://api.ai-analytics.org/clinical/NCT04781686. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*